RSRené Santus

René Santus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


René Santus has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Segmental PASI Evaluation Reveals Reduced PUVA Responsiveness of Lower-Limb Psoriasis in Patients with Internal Organ Malignancy

    by Miguel Alpalhão, Joana Antunes, João Augusto Ferreira, René Santus, Paulo Filipe

    Background/Objectives: The management of moderate-to-severe psoriasis in patients with a recent history of internal malignancy is a clinical challenge, as systemic immunosuppressive therapies are often avoided because of concerns about cancer recurrence. While Psoralen and Ultraviolet A (PUVA) photochemotherapy remains a valuable non-immunosuppressive alternative, regional variations in therapeutic response are not well-characterized in this population. This study aimed to evaluate total and segmental Psoriasis Area and Severity Index (PASI) responses to PUVA in patients with chronic plaque psoriasis and recent internal organ malignancy. Methods: This prospective, single-center, real-world cohort study enrolled 20 adults with moderate-to-severe chronic plaque psoriasis and a recent (p < 0.001). However, regional responses differed significantly: the head and neck improved the most (80.4%), followed by the trunk (72.2%) and upper limbs (72.3%), while the lower limbs showed the weakest response (59.5%; p < 0.001). At baseline, trunk contributed the most to total PASI (38%), while post-treatment, lower-limb lesions accounted for approximately 47% of the remaining total disease burden, showing the highest contribution to total PASI of all body regions. At 6 months, the lower limbs remained the most affected area, with significantly lower improvement (52.9%) compared to other regions. Mean DLQI also improved significantly from 17.2 ± 2.8 to 5.6 ± 2.6 (p < 0.001). Conclusions: PUVA is an effective and safe treatment for patients with psoriasis and a recent history of malignancy. Nevertheless, lower-limb psoriasis is relatively recalcitrant and contributes disproportionately to residual disease burden and relapse. These findings support the use of regional PASI assessment to guide individualized management and clinical expectations in this complex patient group.


  • A tribute to Prof. Miguel Angel Miranda

    by José V. Castell, Hermenegildo García, Avelino Corma, Virginie Lhiaubet, Waldemar Adam, Juan C. Scaiano, René Santus, Eugenio Coronado, Pål Kristian Selbo, Jaime Primo, et al.

  • Narrowband-UVB may restore adalimumab efficacy in chronic plaque psoriasis patients: A prospective exploratory cohort study

    by Inês Tribolet de Abreu, René Santus, João Ferreira, Paulo Filipe

    Biologic therapies (BT) have revolutionized psoriasis management, yet secondary treatment failure remains a significant challenge. Narrowband ultraviolet B (NB-UVB) phototherapy is an established treatment with local immunomodulatory effects that may synergize with BT to restore efficacy. Evidence supporting this approach, particularly regarding adalimumab failure, is limited. In this prospective, exploratory cohort study, 11 adults with chronic plaque psoriasis exhibiting secondary loss of response to adalimumab (without anti-adalimumab antibodies) underwent adjunctive NB-UVB phototherapy three times weekly for 25–30 sessions, while continuing adalimumab 40 mg biweekly. Disease severity was assessed using the Psoriasis Area and Severity Index (PASI). Clinical response was defined as ≥ 50% PASI reduction from flare or return to baseline PASI. Mean PASI increased from 4.1 ± 0.7 at baseline to 11.8 ± 1.6 at flare. Following NB-UVB, mean PASI decreased to 6.2 ± 3.2 (p = 0.006). Excluding non-responders, PASI was 4.0 ± 0.5, comparable to pre-flare values. Five patients (45,5%) achieved PASI 50, two of whom (18.2%) achieved PASI 75. Responses were sustained for at least 24 months. DLQI improved from 14.7 ± 2.4 at flare to 5.6 ± 6.2 after NB-UVB (p = 0.005), indicating a substantial reduction in disease burden. NB-UVB was well tolerated, with no significant adverse events. Three non-responders switched to ustekinumab. Adjunctive NB-UVB phototherapy restored adalimumab efficacy in a majority of patients experiencing secondary failure, offering a safe, accessible, and cost-conscious strategy. Larger controlled studies are warranted to confirm efficacy, elucidate mechanisms, and define the role of combination therapy in modern psoriasis management. Graphical Abstract